Your browser doesn't support javascript.
loading
Actiflagelin, a new sperm activator isolated from Walterinnesia aegyptia venom using phenotypic screening
El-Aziz, Tarek Mohamed Abd; Khoury, Sawsan Al; Jaquillard, Lucie; Triquigneaux, Mathilde; Martinez, Guillaume; Bourgoin-Voillard, Sandrine; Sève, Michel; Arnoult, Christophe; Beroud, Rémy; Waard, Michel De.
  • El-Aziz, Tarek Mohamed Abd; Université de Nantes, Inserm et CNRS. Institute of Thorax. Nantes. FR
  • Khoury, Sawsan Al; Université de Nantes, Inserm et CNRS. Institute of Thorax. Nantes. FR
  • Jaquillard, Lucie; Smartox Biotechnology. Saint-Egrève. FR
  • Triquigneaux, Mathilde; Smartox Biotechnology. Saint-Egrève. FR
  • Martinez, Guillaume; University Grenoble Alpes. Grenoble. FR
  • Bourgoin-Voillard, Sandrine; University Grenoble Alpes. Grenoble. FR
  • Sève, Michel; University Grenoble Alpes. Grenoble. FR
  • Arnoult, Christophe; University Grenoble Alpes. Grenoble. FR
  • Beroud, Rémy; Smartox Biotechnology. Saint-Egrève. FR
  • Waard, Michel De; Université de Nantes, Inserm et CNRS. Nantes. FR
Article in English | LILACS | ID: biblio-894172
ABSTRACT
Sperm contains a wealth of cell surface receptors and ion channels that are required for most of its basic functions such as motility and acrosome reaction. Conversely, animal venoms are enriched in bioactive compounds that primarily target those ion channels and cell surface receptors. We hypothesized, therefore, that animal venoms should be rich enough in sperm-modulating compounds for a drug discovery program. Our objective was to demonstrate this fact by using a sperm-based phenotypic screening to identify positive modulators from the venom of Walterinnesia aegyptia. Methods Herein, as proof of concept that venoms contain interesting compounds for sperm physiology, we fractionated Walterinnesia aegyptia snake venom by RP-HPLC and screened for bioactive fractions capable of accelerating mouse sperm motility (primary screening). Next, we purified each compound from the positive fraction by cation exchange and identified the bioactive peptide by secondary screening. The peptide sequence was established by Edman sequencing of the reduced/alkylated compound combined to LC-ESI-QTOF MS/MS analyses of reduced/alkylated fragment peptides following trypsin or V8 protease digestion. Results Using this two-step purification protocol combined to cell phenotypic screening, we identified a new toxin of 7329.38 Da (actiflagelin) that activates sperm motility in vitro from OF1 male mice. Actiflagelin is 63 amino acids in length and contains five disulfide bridges along the proposed pattern of disulfide connectivity C1-C5, C2-C3, C4- C6, C7-C8 and C9-C10. Modeling of its structure suggests that it belongs to the family of three finger toxins with a noticeable homology with bucandin, a peptide from Bungarus candidus venom. Conclusions This report demonstrates the feasibility of identifying profertility compounds that may be of therapeutic potential for infertility cases where motility is an issue.(AU)
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: Sperm Motility / Spermatozoa / Elapid Venoms / Phospholipases A2 Type of study: Diagnostic study / Practice guideline / Screening study Limits: Animals Language: English Journal: J. venom. anim. toxins incl. trop. dis Journal subject: Toxicology Year: 2018 Type: Article / Project document Affiliation country: France Institution/Affiliation country: Smartox Biotechnology/FR / University Grenoble Alpes/FR / Université de Nantes, Inserm et CNRS/FR

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Sperm Motility / Spermatozoa / Elapid Venoms / Phospholipases A2 Type of study: Diagnostic study / Practice guideline / Screening study Limits: Animals Language: English Journal: J. venom. anim. toxins incl. trop. dis Journal subject: Toxicology Year: 2018 Type: Article / Project document Affiliation country: France Institution/Affiliation country: Smartox Biotechnology/FR / University Grenoble Alpes/FR / Université de Nantes, Inserm et CNRS/FR